BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27750215)

  • 1. Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era.
    Wang Q; Qin Y; Zhou S; He X; Yang J; Kang S; Liu P; Yang S; Zhang C; Gui L; Sun Y; Shi Y
    Oncotarget; 2016 Nov; 7(44):72219-72228. PubMed ID: 27750215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.
    Diefenbach CS; Li H; Hong F; Gordon LI; Fisher RI; Bartlett NL; Crump M; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Stewart DA; Kahl BS; Friedberg JW; Blum KA; Habermann TM; Tuscano JM; Hoppe RT; Horning SJ; Advani RH
    Br J Haematol; 2015 Nov; 171(4):530-8. PubMed ID: 26343802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era.
    Wang Q; Qin Y; Kang SY; He XH; Liu P; Yang S; Zhou SY; Zhang CG; Gui L; Yang JL; Sun Y; Shi YK
    Chin Med J (Engl); 2016 Dec; 129(23):2780-2785. PubMed ID: 27900988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-2 microglobulin as a significant prognostic factor and a new risk model for patients with diffuse large B-cell lymphoma.
    Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
    Hematol Oncol; 2017 Dec; 35(4):440-446. PubMed ID: 27238634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of lymphocyte/monocyte ratio in advanced Hodgkin lymphoma: correlation with International Prognostic Score and tumor associated macrophages.
    Jakovic LR; Mihaljevic BS; Andjelic BM; Bogdanovic AD; Perunicic Jovanovic MD; Babic DD; Bumbasirevic VZ
    Leuk Lymphoma; 2016 Aug; 57(8):1839-47. PubMed ID: 26727349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era.
    Moccia AA; Donaldson J; Chhanabhai M; Hoskins PJ; Klasa RJ; Savage KJ; Shenkier TN; Slack GW; Skinnider B; Gascoyne RD; Connors JM; Sehn LH
    J Clin Oncol; 2012 Sep; 30(27):3383-8. PubMed ID: 22869887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classical Hodgkin lymphoma, lymphocyte depleted type: clinicopathological analysis and prognostic comparison with other types of classical Hodgkin lymphoma.
    Karube K; Niino D; Kimura Y; Ohshima K
    Pathol Res Pract; 2013 Apr; 209(4):201-7. PubMed ID: 23478005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
    Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
    Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy.
    Nakajima Y; Tomita N; Watanabe R; Ishiyama Y; Yamamoto E; Ishibashi D; Itabashi M; Koyama S; Takahashi H; Numata A; Takasaki H; Kawasaki R; Kuwabara H; Tanaka M; Hashimoto C; Fujimaki K; Sakai R; Motomura S; Ishigatsubo Y
    Med Oncol; 2014 Sep; 31(9):185. PubMed ID: 25142947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy.
    Fernandez-Alvarez R; Gonzalez-Rodriguez AP; Gonzalez ME; Rubio-Castro A; Dominguez-Iglesias F; Solano J; Alonso-Nogues E; Fernandez-Alvarez C; Zanabili Y; Alonso JM; Payer AR; Vicente JM; Medina J; Sancho JM
    Leuk Lymphoma; 2015; 56(11):3096-102. PubMed ID: 25860241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series.
    Guisado-Vasco P; Arranz-Saez R; Canales M; Cánovas A; Garcia-Laraña J; García-Sanz R; Lopez A; López JL; Llanos M; Moraleda JM; Rodriguez J; Rayón C; Sabin P; Salar A; Marín-Niebla A; Morente M; Sánchez-Godoy P; Tomás JF; Muriel A; Abraira V; Piris MA; Garcia JF; Montalban C;
    Leuk Lymphoma; 2012 May; 53(5):812-9. PubMed ID: 22185637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
    Chronowski GM; Wilder RB; Tucker SL; Ha CS; Sarris AH; Hagemeister FB; Barista I; Hess MA; Cabanillas F; Cox JD
    Cancer; 2002 Dec; 95(12):2534-8. PubMed ID: 12467067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma.
    Vassilakopoulos TP; Nadali G; Angelopoulou MK; Siakantaris MP; Dimopoulou MN; Kontopidou FN; Karkantaris C; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Pizzolo G; Pangalis GA
    Haematologica; 2002 Jul; 87(7):701-8; discussion 708. PubMed ID: 12091120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic value of beta-2-microglobulin in Hodgkin disease in young adults].
    Fleury J; Tortochaux J; Legros M; Cure H; Kwiatkowski F; Ferrière JP; Travade P; Dionet C; Gaillard G; Chassagne J
    Bull Cancer; 1994 Jul; 81(7):625-31. PubMed ID: 7742606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience.
    Advani RH; Hoppe RT; Maeda LS; Baer DM; Mason J; Rosenberg SA; Horning SJ
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1374-9. PubMed ID: 20934280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: a retrospective study.
    Yang M; Ping L; Liu W; Xie Y; Aliya ; Liu Y; Nuersulitan R; Zhu J; Wu M; Song Y
    Hematology; 2019 Dec; 24(1):413-419. PubMed ID: 30922173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
    Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
    Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphoma.
    Tao Y; Chen H; Zhou Y; He X; Qin Y; Liu P; Zhou S; Yang J; Zhou L; Zhang C; Yang S; Gui L; Shi Y
    Asia Pac J Clin Oncol; 2022 Oct; 18(5):e486-e494. PubMed ID: 35238169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma.
    Reddy JP; Hernandez M; Gunther JR; Dabaja BS; Martin GV; Jiang W; Akhtari M; Allen PK; Atkinson BJ; Smith GL; Pinnix CC; Milgrom SA; Abou Yehia Z; Osborne EM; Oki Y; Lee H; Hagemeister F; Fanale MA
    Br J Haematol; 2018 Feb; 180(4):545-549. PubMed ID: 29271057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.